Recently, a leading Chinese developer of particle therapy equipment announced the completion of a RMB 1 billion (approximately USD 140 million) Series C financing round—the largest single fundraising to date in this specialized sector. The round was co-led by prominent healthcare-focused investment funds and state-backed capital. Proceeds will be used to accelerate clinical validation, regulatory approval, and commercialization of domestically developed proton and heavy-ion therapy systems, as well as to advance core technology R&D and expand global market presence.Particle therapy—including proton and carbon-ion therapy—is widely recognized as one of the most advanced forms of radiation oncology, offering superior precision, reduced side effects, and enhanced efficacy, particularly for pediatric cancers and tumors located in complex anatomical regions. Historically, high-end particle therapy systems have been dominated by foreign manufacturers, with each unit costing hundreds of millions of RMB, significantly limiting accessibility in China.This successful funding round underscores strong investor confidence in China’s capacity for indigenous innovation in high-end medical devices and aligns with national strategies to promote domestic alternatives and improve cancer care. As the company accelerates localization efforts, it is poised to substantially reduce treatment costs, broaden patient access to cutting-edge therapy, and establish China as a competitive player in the global advanced radiotherapy equipment market.
近日，国内领先的粒子治疗设备研发企业宣布完成10亿元人民币的C轮融资，创下该细分领域单轮融资金额新高。本轮融资由多家知名医疗产业基金与国有资本联合领投，资金将主要用于加速国产质子/重离子治疗系统的临床验证、产品注册及商业化落地，并进一步拓展核心技术研发与全球市场布局。粒子治疗（包括质子和重离子治疗）是当前国际公认的最先进放射治疗技术之一，具有精准靶向、副作用小、疗效显著等优势，尤其适用于儿童肿瘤及复杂部位肿瘤的治疗。然而，长期以来，高端粒子治疗设备被国外厂商垄断，单套系统价格高达数亿元，严重制约了该技术在中国的普及应用。此次融资成功标志着资本市场对国产高端医疗装备自主创新能力的高度认可，也反映出国家在推动高端医疗器械国产化、提升癌症诊疗水平方面的坚定决心。随着该企业加速推进设备国产化进程，未来有望大幅降低粒子治疗成本，让更多患者受益于这一尖端技术，同时助力中国在全球高端放疗设备市场中占据一席之地。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/5890.html